
Myomo (MYO) Stock Forecast & Price Target
Myomo (MYO) Analyst Ratings
Bulls say
Myomo Inc. demonstrated impressive financial performance, reporting record quarterly revenues of $12.1 million, a 154% increase year-over-year and surpassing consensus estimates significantly. The company's strong revenue growth was bolstered by an increased average selling price driven by a higher volume of Medicare patients, alongside a 106% year-over-year rise in total revenue units, contributing to optimistic projections of total revenue reaching $52.3 million in 2025. Additionally, Myomo's gross margin improved to 71%, a notable increase from 65% in the previous quarter, while adding 657 new patient candidates to its pipeline, reflecting strong operational momentum in the growing myoelectric orthotics market.
Bears say
Myomo Inc. faces a declining backlog of insurance-authorized orders, decreasing from 316 in the previous quarter to 272, which raises concerns about future revenue generation. The company reported a net loss of $0.01 per share, which, although slightly better than analyst expectations of a $0.02 loss, still highlights ongoing financial challenges and operational inefficiencies. Additionally, several fundamental risks, including liquidity issues, regulatory hurdles, and competition in the healthcare market, contribute to a negative outlook for the stock, suggesting that the potential for growth may not suffice to outweigh these substantial concerns.
This aggregate rating is based on analysts' research of Myomo and is not a guaranteed prediction by Public.com or investment advice.
Myomo (MYO) Analyst Forecast & Price Prediction
Start investing in Myomo (MYO)
Order type
Buy in
Order amount
Est. shares
0 shares